Skip navigation
Covered by Medicare for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal cancer

Signatera™ for Gynecologic Cancers

Monitor your patients with gynecologic cancer using tumor-informed ctDNA testing to inform management decisions.

Power Clinical Decisions in Gynecologic Cancer


Understand Risk

after completion of adjuvant/definitive therapy, ctDNA was detectable in


of patients, all of whom experienced disease progression (HR: 17.6 95%CI: 3.2-97.4, p<0.001)1


Detect Recurrence Earlier

Longitudinally, ctDNA was detected with


sensitivity and specificity while CA-125 had much lower sensitivity (43%) and specificity (78%)1,2


Predict Treatment Response

After just 2 cycles of immunotherapy


of patients with an increase in ctDNA did not derive an objective response to treatment3*

Get Started

Actionable Molecular Insights Across the Patient Journey

Signatera™ enables early detection of molecular residual disease (MRD) to help you manage your patients with gynecologic cancers.

alt text
  • Discover the Data in Gynecologic Cancers

  • Signatera™ is clinically validated cross multiple indications.
  • Post-Adjuvant MRD assessment
    First-Line Therapy
    • After completion of adjuvant/definitive therapy, ctDNA was detectable in 23% of patients, all of whom experienced disease progression.1
    Learn More
  • Surveillance/Maintenance
  • Treatment Response Monitoring

Monitor Your Patients With Confidence

As part of her ovarian cancer monitoring plan, Anne received Signatera™ testing and CA-125 at regular intervals.

A positive Signatera™ result alerted her oncologist to order a scan, which caught a recurrence early. Now, Anne is receiving Signatera™ to monitor response to her maintenance therapy. Since starting therapy, Anne’s Signatera™ results have been negative, so she can feel more confident about her treatment plan.

Tailor Gynecologic Cancer Treatment With Natera’s Portfolio of Genomic Tests

Signatera™ Highly sensitive and perosnalized tumor-informed test for molecular residual disease (MRD) detection
Altera™ Comprehensive genomic profiling for clinically relevant biomarkers that may help guide treatment selection (including MSI, BRCA1/2, HR genes, MMR genes, TMB, BRAF, RET, and NTRK), with no additional tumor sample needed.
Empower™ Germline genetic test for commonly screened genes in gynecologic cancers (eg BRCA 1/2, MMR genes) to inform therapeutic decisions.

More Clinician Resources

Signatera™ in Gynecologic Cancers

Read about the clinical utility of the Signatera™ test and data for MRD assessment, recurrence monitoring, and IO treatment response monitoring.

IO Monitoring Brochure

Learn how Signatera™ can assess immunotherapy response as early as 6 weeks into treatment for patients with ovarian, cervical, endometrial, and other cancers.2

Ready to try Signatera™ for your gynecologic cancer patients?

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Hou et al. Gynecol Oncol. 2022; 167:334-341.

2Chapman et al. Poster presented at 2021 AACR Annual Meeting.

3Bratman et al. Nature Cancer. 2020; 1(9):873-881.


*Includes high grade serous ovarian cancer (n=18), endometrial cancer (n=2), and cervical cancer (n=1).

icon-angle icon-bars icon-times